Strategic Intelligence: Navigating shifts in pharmaceutical patent litigation
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For more than 25 years, life science companies, law firms, and regulatory agencies around the globe have turned to CRA’s life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.
Key expert takeaways on the IRA, European court expansion, and patent delisting for life sciences leaders.
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...
CRA is a proud sponsor of Europe’s largest congress in market access, pricing and evidence featuring 250 speakers, 10 tracks and 1500+ attendees from pharma,...
Investing in the prevention and treatment of non-communicable diseases (NCDs) can strengthen health systems, protect economic productivity, and improve...
Last year, Regeneron took to trial its case alleging exclusionary conduct through bundled rebates by competitor Amgen. The jury found for Regeneron, awarding...
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
